DrugPatentWatch Database Preview
Ibritumomab tiuxetan - Biologic Drug Details
» See Plans and Pricing
Summary for ibritumomab tiuxetan
Tradenames: | 1 |
Patents: | 162 |
Applicants: | 1 |
BLAs: | 1 |
Recent Clinical Trials: | See clinical trials for ibritumomab tiuxetan |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ibritumomab tiuxetan |
Recent Clinical Trials for ibritumomab tiuxetan
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 3 |
University of California, Davis | Phase 2 |
Spectrum Pharmaceuticals, Inc | Phase 3 |
Recent Litigation for ibritumomab tiuxetan
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
GENENTECH, INC. v. CELLTRION, INC. | 2018-01-11 |
GENENTECH, INC. v. SANDOZ, INC. | 2017-12-20 |
See all ibritumomab tiuxetan litigation
PTAB Litigation
Petitioner | Date |
---|---|
2017-12-20 |
Company Disclosures: US Patents for ibritumomab tiuxetan
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Idec Pharmaceuticals Corporation (San Diego, CA) | 2015-04-07 | RX | Orphan | company |
Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceuticals Corporation (San Diego, CA) | 2015-07-07 | RX | Orphan | company |
Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | 2015-12-01 | RX | Orphan | company | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for ibritumomab tiuxetan
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corpoartion (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ibritumomab tiuxetan
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 233779 | Start Trial |
European Patent Office | 2473186 | Start Trial |
European Patent Office | 2358760 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ibritumomab tiuxetan
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
C/GB04/025 | United Kingdom | Start Trial | PRODUCT NAME: IBRITUMOMAB COMPRISING A CHELATING AGENT FOR YTTRIUM (90); REGISTERED: UK EU/1/03/264/001 20040116 |
04C/016 | Belgium | Start Trial | PRODUCT NAME: IBRITUMOMAB; AUTHORISATION NUMBER AND DATE: EU/1/03/264/001 20040119 |
2016 00031 | Denmark | Start Trial | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |